Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 33 | 2025 | 354 | 13.830 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 944 | 3.340 |
Why?
|
| Neoplasm, Residual | 10 | 2024 | 194 | 3.270 |
Why?
|
| Dexamethasone | 11 | 2024 | 351 | 2.520 |
Why?
|
| Oligopeptides | 5 | 2024 | 195 | 1.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 2642 | 1.530 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 91 | 1.370 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 1431 | 1.250 |
Why?
|
| Transplantation, Autologous | 9 | 2023 | 362 | 1.160 |
Why?
|
| Mass Spectrometry | 2 | 2025 | 206 | 1.110 |
Why?
|
| Myeloma Proteins | 2 | 2025 | 39 | 1.100 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 372 | 1.050 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 37 | 0.990 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2025 | 277 | 0.980 |
Why?
|
| Paraproteinemias | 2 | 2025 | 19 | 0.970 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2024 | 12 | 0.950 |
Why?
|
| Geriatric Assessment | 4 | 2024 | 192 | 0.940 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 10 | 0.930 |
Why?
|
| Premedication | 1 | 2024 | 58 | 0.870 |
Why?
|
| Humans | 52 | 2025 | 96175 | 0.840 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2021 | 2 | 0.720 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 3 | 0.720 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 2422 | 0.710 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 297 | 0.670 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 21 | 0.660 |
Why?
|
| Middle Aged | 20 | 2025 | 28374 | 0.660 |
Why?
|
| Aged | 18 | 2025 | 20970 | 0.650 |
Why?
|
| Amyloidosis | 1 | 2022 | 139 | 0.640 |
Why?
|
| Cancer Survivors | 1 | 2021 | 87 | 0.630 |
Why?
|
| Daunorubicin | 1 | 2019 | 78 | 0.620 |
Why?
|
| Cytarabine | 1 | 2019 | 225 | 0.590 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 135 | 0.590 |
Why?
|
| Bacterial Infections | 1 | 2020 | 185 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1097 | 0.560 |
Why?
|
| Disease Management | 2 | 2020 | 360 | 0.560 |
Why?
|
| Remission Induction | 1 | 2019 | 769 | 0.540 |
Why?
|
| Preoperative Care | 1 | 2019 | 418 | 0.520 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2017 | 1 | 0.520 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2017 | 12 | 0.520 |
Why?
|
| Patient Care Team | 1 | 2019 | 308 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 350 | 0.500 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 841 | 0.500 |
Why?
|
| Adult | 12 | 2025 | 28729 | 0.480 |
Why?
|
| Male | 18 | 2025 | 45884 | 0.480 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 9 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 570 | 0.460 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 192 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 423 | 0.460 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 683 | 0.450 |
Why?
|
| Precision Medicine | 1 | 2019 | 451 | 0.450 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2025 | 25 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 650 | 0.440 |
Why?
|
| Female | 18 | 2025 | 50079 | 0.430 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 7234 | 0.430 |
Why?
|
| T-Lymphocytes | 4 | 2025 | 1316 | 0.420 |
Why?
|
| Maintenance Chemotherapy | 2 | 2024 | 91 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 886 | 0.390 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2025 | 82 | 0.390 |
Why?
|
| Physicians | 1 | 2020 | 711 | 0.390 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 257 | 0.380 |
Why?
|
| Consensus | 2 | 2024 | 370 | 0.370 |
Why?
|
| Flow Cytometry | 2 | 2024 | 727 | 0.320 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 539 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2025 | 9176 | 0.280 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 901 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1172 | 0.270 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2025 | 2 | 0.230 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2025 | 7 | 0.230 |
Why?
|
| Quality of Life | 2 | 2024 | 1818 | 0.220 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 134 | 0.220 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2463 | 0.210 |
Why?
|
| Withholding Treatment | 1 | 2024 | 121 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 1195 | 0.200 |
Why?
|
| CD3 Complex | 1 | 2023 | 136 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2866 | 0.200 |
Why?
|
| Hypercalcemia | 1 | 2023 | 62 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2024 | 111 | 0.190 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.190 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 54 | 0.190 |
Why?
|
| Bortezomib | 1 | 2022 | 82 | 0.190 |
Why?
|
| Melphalan | 1 | 2022 | 100 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2024 | 458 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2025 | 763 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 313 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2025 | 408 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 199 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 94 | 0.170 |
Why?
|
| Bone Marrow Examination | 1 | 2020 | 46 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 70 | 0.160 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 286 | 0.160 |
Why?
|
| Asparaginase | 1 | 2019 | 35 | 0.160 |
Why?
|
| Philadelphia Chromosome | 1 | 2019 | 44 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 104 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2020 | 296 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.150 |
Why?
|
| Reference Standards | 1 | 2019 | 150 | 0.150 |
Why?
|
| Standard of Care | 1 | 2019 | 70 | 0.150 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 393 | 0.150 |
Why?
|
| Allografts | 1 | 2019 | 207 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2020 | 339 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 273 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 192 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 377 | 0.130 |
Why?
|
| Sex Factors | 1 | 2020 | 1134 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 1023 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1665 | 0.130 |
Why?
|
| Neoplasms | 2 | 2023 | 3250 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 939 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2017 | 228 | 0.130 |
Why?
|
| Prognosis | 2 | 2023 | 4033 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 1020 | 0.120 |
Why?
|
| Rituximab | 1 | 2017 | 133 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2023 | 10290 | 0.120 |
Why?
|
| Time Factors | 3 | 2020 | 5585 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 709 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2042 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1569 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 151 | 0.120 |
Why?
|
| Splanchnic Circulation | 1 | 2015 | 14 | 0.120 |
Why?
|
| Body Weight | 1 | 2017 | 460 | 0.120 |
Why?
|
| Neutrophils | 1 | 2017 | 334 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 489 | 0.110 |
Why?
|
| Serial Publications | 1 | 2014 | 2 | 0.110 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 15 | 0.110 |
Why?
|
| Science | 1 | 2014 | 37 | 0.100 |
Why?
|
| Reproduction | 1 | 2014 | 203 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2020 | 4673 | 0.090 |
Why?
|
| United States | 1 | 2024 | 7774 | 0.080 |
Why?
|
| Child | 1 | 2019 | 7629 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 626 | 0.070 |
Why?
|
| Risk Factors | 2 | 2015 | 5962 | 0.070 |
Why?
|
| Thalidomide | 1 | 2024 | 56 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2023 | 48 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 481 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 7027 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 147 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 24 | 0.050 |
Why?
|
| Adolescent | 1 | 2015 | 9899 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 60 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 323 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 181 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 432 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 191 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 226 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 122 | 0.040 |
Why?
|
| Autografts | 1 | 2020 | 33 | 0.040 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2020 | 4 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 188 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 348 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 74 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 312 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 74 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 3147 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 218 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 216 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 213 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1469 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 475 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1178 | 0.030 |
Why?
|
| PubMed | 1 | 2014 | 16 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2882 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2581 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 28 | 0.030 |
Why?
|
| Postmenopause | 1 | 2013 | 107 | 0.020 |
Why?
|
| Research | 1 | 2014 | 265 | 0.020 |
Why?
|
| Women's Health | 1 | 2013 | 109 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 273 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 3108 | 0.020 |
Why?
|